Long-term Ozanimod Delivers No Evidence of Disease Activity

Patients with relapsing multiple sclerosis (RMS) achieved No Evidence of Disease Activity more frequently if they had received long-term continuous ozanimod therapy than if they had received interferon or transitioned from interferon to ozanimod, a post-hoc analysis of the phase 3 RADIANCE trial and the open-label extension DAYBREAK study showed.

Related Keywords

United States , Switzerland , American , , Ludwig Kappos University Of Basel , American Academy Of Neurology , Disease Activity , Ludwig Kappos , American Academy , Great Neuro , Patients With Relapsing Multiple Sclerosis , Post Hoc Analysis , Open Label Extension Studies ,